Albert B Sabin Vaccine Institute Inc
Programs
Vaccine Research and Development
Vaccine Research & DevelopmentThe Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's Research & Development strategy is to advance the development of vaccine candidates that have demonstrated early scientific value but have little commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public, and private sectors, and promotes open-source research. Ebola has taken the lives of more than 15,000 people in the last many years. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is currently developing vaccines for Sudan ebolavirus and Marburg virus diseases based on technology licensed from GSK. The prophylactic vaccine candidates are based on GSK's proprietary ChAd3 platform. In 2019, the U.S. Health and Human Services' Biomedical Advanced Research and Development Authority awarded Sabin a multi-year development contract to advance development of the Marburg and Sudan Ebola vaccines.GeographiesNot indicatedDatesJan 1, 2023 – Dec 31, 2023Source990No causes providedNo populations provided–$27.1MGlobal Immunization Programs
Global ImmunizationDespite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by immunization. Sabin has a vision of a future free from such preventable diseases. Reaching this goal requires efficient vaccine distribution, broad vaccine uptake and equitable access to vaccination services. Through advocacy, capacity development and social, behavioral, and epidemiological research, Sabin advances evidence-based strategies for improved distribution and uptake of vaccines. Sabin's Global Immunization programs focus on turning vaccines into vaccinations by ceding power, resources, and decision-making to community and national stakeholders. They build consensus to mobilize action through stakeholder consortiums and convenings; strengthen the capabilities of local immunization professionals to deliver vaccinations to remote and hard-to-reach settings; co-design implementation research studies with community-based investigators to highlight barriers for vaccine uptake; and apply epidemiology for disease surveillance as well as optimizing vaccine use. Sabin's Boost global community enables immunization professionals to connect with peers and experts, learn skills that build capacity and advance careers, and lead immunization programs in challenging contexts. Sabin's Vaccine Acceptance & Delivery workstream focuses on understanding the social drivers of vaccination decisions to improve uptake and confidence. Sabin's Applied Epidemiology team improves disease outcomes by generating essential epidemiological data for well-designed and efficiently implemented immunization programs and creating cost-effective diagnostics for diseases such as typhoid. Through a variety of mechanisms including the Global HPV Consortium and the Coalition Against Typhoid, Sabin brings together researchers, government officials, immunization specialists, and other stakeholders to support the introduction and expansion of new under-utilized vaccines.GeographiesNot indicatedDatesJan 1, 2023 – Dec 31, 2023Source990No causes providedNo populations provided–$10.2M
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)